文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

GATA2缺陷与MDS/AML:疾病建模的实验策略及未来治疗前景

GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
PubMed 文献 · Br J Haematol · 2022-06-26

该综述由ERAPerMed GATA2 HuMo联盟撰写,阐述家族性GATA2缺陷相关MDS的遗传、临床与生物学特征,指出GATA2缺陷是青少年单体7型MDS最常见的遗传病因,异基因造血干细胞移植是唯一治愈手段,但缺乏预测工具且家族内异质性机制不明,强调需建立可靠的临床前疾病模型以改善早期检测和临床决策。

要点

  • GATA2缺陷是异质性免疫缺陷综合征,终生进展为MDS和AML风险极高。
  • GATA2缺陷是青少年单体7型MDS最常见的遗传病因。
  • 异基因造血干细胞移植是唯一治愈手段,但免疫缺陷和MDS进展会降低生存机会。

核心结论

  • GATA2缺陷相关家族性MDS存在明确的未满足医疗需求,需开发可靠的临床前疾病模型以改善GATA2携带者的早期检测和临床决策。

研究设计与样本

  • 综述,由ERAPerMed GATA2 HuMo联盟撰写,描述家族性GATA2相关MDS的遗传、临床和生物学方面。

主要发现

  • GATA2缺陷是异质性免疫缺陷综合征,终生进展为MDS和AML风险极高。
  • GATA2缺陷被确定为青少年单体7型MDS最常见的遗传病因。
  • 携带GATA2突变的家系中外显率和表现度常可变,提示需协同的外源性事件触发疾病。
  • 缺乏预测工具,家族内异质性机制了解甚少。

临床怎么用

  • 异基因造血干细胞移植是唯一治愈选择,但生存机会随免疫缺陷进展和MDS演变而降低。

局限性

  • 缺乏预测工具,家族内异质性了解甚少。
  • 存在明确的未满足医疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kotmayer L, Romero-Moya D, Marin-Bejar O, et al. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. Br J Haematol. 2022. PMID: 35753998. doi:10.1111/bjh.18330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。